1. Search Result
Search Result
Results for "

adult rats

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Peptides

3

Natural
Products

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-Y0966
    Glycine
    10+ Cited Publications

    Environmental Pollutants Endogenous Metabolite iGluR VEGFR Ninjurin Infection Neurological Disease Inflammation/Immunology Cancer
    Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
    Glycine
  • HY-Y0966R
    Glycine (Standard)
    1 Publications Verification

    Reference Standards Endogenous Metabolite iGluR VEGFR Neurological Disease
    Glycine (Standard) is the analytical standard of Glycine. This product is intended for research and analytical applications. Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
    Glycine (Standard)
  • HY-P3281

    FGFR Neurological Disease
    FGL peptide is a fibroblast growth factor receptor (FGFR) modulator and blood-brain barrier-penetrant. FGL peptide activates NCAM-FGFR and FGFR1 signaling pathways. FGL peptide alters expression of apoptosis, signal transduction and metabolism regulator genes in traumatic brain injury contexts. FGL peptide can be used for the research of traumatic brain injury .
    FGL peptide
  • HY-14785

    NLX-112; F13640

    5-HT Receptor Neurological Disease
    Befiradol (NLX-112) is a highly selective 5-HT1A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol can be used in studies related to opioid-induced respiratory depression .
    Befiradol
  • HY-W073128

    PFTeDA

    PPAR Apoptosis PGC-1α AMPK Akt mTOR Reactive Oxygen Species (ROS) Endocrinology
    Perfluorotetradecanoic acid (PFTeDA) is an orally active perfluoroalkyl substance. Perfluorotetradecanoic acid directly binds to the ligand-binding domain of purified hPPARγ, with a Kd value of 157.8 μM. Perfluorotetradecanoic acid significantly reduces the activity of the SIRT1/PGC1α and AMPK signaling pathways while stimulating the activity of the AKT1/mTOR signaling pathway. Perfluorotetradecanoic acid significantly upregulates the expression of corticosterone biosynthesis genes. Perfluorotetradecanoic acid increases ROS levels and promotes Apoptosis. Perfluorotetradecanoic acid impairs Leydig cell function and male reproductive endocrine function in adult male rats .
    Perfluorotetradecanoic acid
  • HY-W275295

    PFDoA

    Reactive Oxygen Species (ROS) Caspase Mitochondrial Metabolism Neurological Disease Metabolic Disease
    Perfluorododecanoic acid (PFDoA) is an orally active, blood-brain barrier-permeable perfluorinated compound. Perfluorododecanoic acid increases Caspase 3 activity, disrupts mitochondrial membrane potential, and elevates ROS levels. Perfluorododecanoic acid induces cognitive deficits. Perfluorododecanoic acid exhibits hepatotoxicity .
    Perfluorododecanoic acid
  • HY-N11424

    Drug Metabolite Glycosyltransferase Metabolic Disease
    Bilirubin diglucuronide is a bilirubin glycoside conjugate with a 1-O-acyl β-D-glucuronide structure. Bilirubin diglucuronide is the major conjugated bilirubin (HY-N0323) and predominant pigment excreted in the bile of adult humans, rats, dogs and cats. Bilirubin diglucuronide is mainly synthesized via UDP-glucuronosyltransferase-mediated transfer of glucuronic acid from UDP-glucuronic acid to bilirubin monoglucuronide, or via enzymatic disproportionation of two moles of bilirubin monoglucuronide (predominantly producing the IXα configuration). In addition, Bilirubin diglucuronide can also be synthesized from bilirubin or its monoglucuronide in a UDP-glucuronic acid-dependent manner. Pretreatment with phenobarbital significantly enhances the formation process of Bilirubin diglucuronide .
    Bilirubin diglucuronide
  • HY-B1017

    EN-1733A

    Dopamine Receptor Neurological Disease
    Molindone hydrochloride (EN-1733A) is an orally active and brain-penetrant dopamine D2/D5 receptor antagonist. Molindone hydrochloride shows antipsychotic and antidepressant-like activities. Molindone hydrochloride suppresses spontaneous locomotion, and antagonizes apomorphine-induced emesis. Molindone hydrochloride can be used for the research of neurological disease .
    Molindone (hydrochloride)
  • HY-14785A

    NLX-112 hydrochloride; F 13640 hydrochloride

    5-HT Receptor Neurological Disease Metabolic Disease
    Befiradol (NLX-112) hydrochloride is a highly selective 5-HT1A receptor agonist that acts on both presynaptic and postsynaptic sites. Befiradol hydrochloride attenuates fentanyl-induced respiratory depression in neonatal and adult rats. Befiradol reduces the duration of fentanyl-induced analgesia and sedation in adult rats. Befiradol hydrochloride can be used in studies related to opioid-induced respiratory depression .
    Befiradol hydrochloride
  • HY-117158

    Adrenergic Receptor Others
    SKF 89748 is an α1-adrenergic receptor agonist with the activity of inhibiting food and water intake. SKF 89748 inhibits food and water intake in adult male rats with an ED50 of 0.37mg/kg for inhibiting food intake.
    SKF 89748
  • HY-155823

    Cholinesterase (ChE) Neurological Disease
    TZ4M is a 2,4-thiazolidinedione (TZD)-based anti-ADV agent with neuroprotective effects. TZ4M exhibits AChE inhibition in human plasma. TZ4M improves memory and cognitive impairment in adult rats in a scopolamine (HY-N0296)-induced Alzheimer-type model .
    TZ4M
  • HY-19078

    Prostaglandin Receptor Cardiovascular Disease
    SQ-30741 is a thromboxane A2 receptor antagonist. SQ-30741 reduces vasoconstriction in a feline pulmonary vascular bed model. SQ-30741 increases relaxation of aortic endothelium and vascular smooth muscle in adult rats in a spontaneously hypertensive rat model. SQ-30741 can be used in research on cardiovascular diseases such as hypertension .
    SQ-30741
  • HY-123664

    LY133314

    Estrogen Receptor/ERR Cancer
    Trioxifene mesylate (LY133314) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene mesylate binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene mesylate can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma .
    Trioxifene mesylate
  • HY-113203A

    Endogenous Metabolite Neurological Disease
    Putreanine dihydrochloride is an alkaline diamino monocarboxylic acid amino acid that exists exclusively in the central nervous system of mammals and birds. Putreanine dihydrochloride reaches its highest concentration in the caudal region of the brain. Putreanine dihydrochloride appears in the brain tissue of rats 2 weeks after birth, and its concentration gradually increases to adult levels over several months .
    Putreanine dihydrochloride
  • HY-W182790

    LSL 60101

    Garsevil (LSL 60101) is a biphasic, selective imidazoline I2 receptor (I2-IR) ligand, with a pKi of 9.03 and a Ki of 0.9 nM at the high-affinity site, and a pKi of 5.25 and a Ki of 5.6 nM at the low-affinity site. Garsevil is applicable to research related to Alzheimer's disease .
    Garsevil
  • HY-135529

    LY133314 free base

    Estrogen Receptor/ERR Cancer
    Trioxifene (LY133314 free base) is an orally active and selective estrogen receptor (ER) modulator with human ERα IC50 of 203.49 nM and Ki of 20.84 nM. Trioxifene binds estradiol receptors, inhibits ERα-mediated gene expression, reduces circulating gonadotrophin levels. Trioxifene can be used for the research of advanced breast cancer and androgen-independent, metastatic prostatic adenocarcinoma .
    Trioxifene

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: